Fewer than
0
%
of all EMA approved orphan medicines are available in all 27 EU member states2
We apply intelligent new approaches to the issues around medicine affordability to broaden patient access to medicines.
Beyond Medicines
Value for Health Systems & Payors
Our approach delivers value beyond medicines for patients, healthcare professionals and healthcare systems.
- Supporting patients to get the most from their medicines
- Supporting clinician-patient conversations
- Championing sustainable access to rare disease medicines
1. Pharmaceutical Technology (2025) Orphan drug market access in Europe: HTA challenges and the growing potential of RWE. Available at: https://www.pharmaceutical-technology.com/sponsored/orphan-drug-market-access-in-europe-hta-challenges-and-the-growing-potential-of-rwe/ (Accessed: 14 March 2026).
2. EFPIA Patients W.A.I.T. Indicator 2024 Survey Published May 2025.
OTD-NP-GBR-00003 | March 2026